SCHEMBL12247263

SCHEMBL12247263

CC1(C)c2ccccc2-c2cc3c(-c4ccc5ccccc5c4)c4ccccc4c(-c4ccc(-c5ccccn5)nc4)c3cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.36
KLF5 Q13887 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PDK2 Q15119 1/20 0.35
HTR2C P28335 1/20 0.33
DCTPP1 Q9H773 1/20 0.32
KDR P35968 1/20 0.32
HPGDS O60760 1/20 0.32
ABL1 P00519 2/20 0.31
CYP2C9 P11712 1/20 0.31
CYP11B1 P15538 1/20 0.30
CYP11B2 P19099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13459681 1.00 KDM4E (0.36) KDM4EALDH1A1LMNATP53MAPT
SCHEMBL12247255 0.95 PDK2 (0.36) KDM4EALDH1A1LMNATP53MAPT
SCHEMBL12247010 0.93 KDM4E (0.37) KDM4EALDH1A1LMNATP53MAPT
SCHEMBL12247260 0.93 PDK2 (0.40) KDM4EALDH1A1LMNATP53PKM
SCHEMBL12247282 0.93 PDK2 (0.40) KDM4EALDH1A1LMNATP53PKM
SCHEMBL12247298 0.93 PDK2 (0.39) KDM4EALDH1A1LMNATP53PKM
SCHEMBL12247332 0.92 KDM4E (0.36) KDM4EALDH1A1LMNATP53MAPT
SCHEMBL12247278 0.91 PDK2 (0.35) KDM4EALDH1A1LMNATP53MAPT
SCHEMBL12247268 0.91 PDK2 (0.35) KDM4EALDH1A1LMNATP53MAPT
SCHEMBL12247321 0.90 KDM4E (0.35) KDM4EALDH1A1LMNATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8525158-B2 Anthracene derivative and organic electroluminescence element using the same DOOSAN CORPORATION (KR) 2013-09-03 US disclosed
US-8525158-B2 Anthracene derivative and organic electroluminescence element using the same DOOSAN CORPORATION (KR) 2013-09-03 US disclosed
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME DOOSAN CORPORATION (KR) 2011-09-01 US disclosed
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME DOOSAN CORPORATION (KR) 2011-09-01 US disclosed
WO-2010027181-A2 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME 주식회사 두산 (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME KCNJ2, KCNJ1, BRD4 KDM4E 913/4885ALDH1A1 710/4885LMNA 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.